免疫治疗难治与alloHCT后早期复发定义CD19 CAR-T后超高危B-ALL
该回顾性EBMT登记研究分析345例接受CART19的R/R B-ALL患者,按既往alloHCT及blinatumomab/InO敏感性分层。中位随访2.3年,3个月MRD阴性CR累积发生率78%,2年OS和EFS分别为65%和49%。免疫治疗难治及alloHCT后<6个月复发独立预测更差EFS。
要点
- 免疫治疗难治(blinatumomab或InO)与CART19后EFS独立变差相关。
- alloHCT后<6个月复发者2年OS仅43%,显著低于≥6个月者的74%。
- alloHCT初治患者中,淋巴清除前形态学病变使EFS风险比达3.34。
核心结论
- 免疫治疗难治性和alloHCT后早期复发(<6个月)是CART19治疗R/R B-ALL的超高危因素,独立预测更差EFS。
研究设计与样本
- 回顾性分析EBMT登记库2016-2023年接受CART19的R/R B-ALL患者345例(成人173例/儿童172例),中位年龄18岁(范围1.1-78.2)。
主要发现
- 中位随访2.3年,3个月MRD阴性完全缓解累积发生率为78%,2年OS为65%、EFS为49%。
- alloHCT初治患者中,blinatumomab难治者2年OS/EFS为31%/17%,blinatumomab应答者为83%/60%,未暴露者为65%/55%。
- alloHCT初治患者中,InO难治者2年OS/EFS为22%/18%,InO应答者为62%/55%,未暴露者为68%/54%。
- alloHCT暴露患者中,InO难治者2年OS/EFS为49%/29%,InO未暴露者为71%/54%,应答者为60%/38%。
- alloHCT后<6个月复发者2年OS为43%、EFS为31%,≥6个月复发者为74%和54%。
关键数值与推荐
- 多因素模型中,免疫治疗难治独立预测更差EFS:alloHCT初治者HR 2.56,alloHCT暴露者HR 2.20。
- alloHCT初治者淋巴清除前形态学病变使EFS风险比达3.34。
- alloHCT后早期复发(<6个月)使EFS风险比达1.85。
临床怎么用
- 对拟行CART19的R/R B-ALL患者,应评估既往blinatumomab和InO的敏感性及alloHCT后复发时间以进行风险分层。
- 免疫治疗难治或alloHCT后早期复发患者应优先考虑临床试验或强化策略。
局限性
- 回顾性登记研究设计可能引入选择偏倚和信息偏倚。
- 原文未报告混杂因素调整细节及亚组样本量,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed CAR T-cell therapy (CART19) has transformed relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) management, but the prognostic impact of immunotherapy sensitivity and post-allogeneic hematopoietic cell transplantation (alloHCT) relapse timing in real-world practice remains unclear. We retrospectively analyzed EBMT registry patients with R/R B-ALL treated with CART19 (2016-2023), stratifying by prior alloHCT and classifying prior blinatumomab and inotuzumab ozogamicin (InO) as naïve, responder (CR/CRi), or refractory. Among 345 patients (173/172 adults/children), median age was 18 years (range 1.1-78.2); 58% were alloHCT-exposed, 27% blinatumomab-exposed, 29% InO-exposed, and 52% had pre-lymphodepletion morphological disease. With a median follow-up of 2.3 years, the 3-month MRD-negative complete remission cumulative incidence was 78%; 2-year overall survival (OS) and event-free survival (EFS) were 65% and 49%. In alloHCT-naïve patients, 2-year OS/EFS were 83%/60% (blinatumomab responders), 65%/55% (blinatumomab-naïve), and 31%/17% (blinatumomab-refractory); for InO, OS/EFS were 68%/54% (naïve), 62%/55% (responders), and 22%/18% (refractory). In alloHCT-exposed patients, blinatumomab category did not discriminate outcomes, whereas InO refractoriness was associated with inferior OS/EFS (49%/29%) versus InO-naïve (71%/54%) and responders (60%/38%). Early relapse after alloHCT (<6 vs ≥6 months) was associated with worse 2-year OS (43% vs 74%) and EFS (31% vs 54%). In multivariable models, immunotherapy refractoriness independently predicted inferior EFS (HR 2.56 in alloHCT-naïve; HR 2.20 in alloHCT-exposed); overt morphological disease at lymphodepletion in alloHCT-naïve (HR 3.34) and early post-alloHCT relapse (HR 1.85) further worsened EFS. These findings support pragmatic pre-CAR T risk stratification and prioritization of trials or intensified strategies for refractory disease and early post-alloHCT relapse.
引用
- Ortiz-Maldonado V, Galimard JE, Ottaviano G, et al. Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy. Blood Adv. 2026. PMID: 42815156. doi:10.1182/bloodadvances.2026019855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。